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Abstract
Objective—The incidence of oral cavity and pharyngeal cancer in Puerto Rican men is higher 
than it is in the men of any other ethnic/racial group in the United States of America (US). The 
information regarding the effect of the human papilloma virus (HPV) in the gene-expression 
profile among patients with this cancer is limited in Hispanic community. We aim to describe the 
methodology for future studies to identify the molecular networks for determining overrepresented 
signaling and metabolic canonical pathways, based on the differential gene-expression profiles of 
HPV+ and HPV− samples from patients with oropharyngeal squamous cell carcinoma in Puerto 
Rico.
Address correspondence to: Erick Suárez, PhD, Department of Biostatistics and Epidemiology, University of Puerto Rico Medical 
Sciences Campus, PO Box 365067, San Juan, PR 00936-5067. erick.suarez@upr.edu. 
The authors have no conflict of interest to disclose.
HHS Public Access
Author manuscript
P R Health Sci J. Author manuscript; available in PMC 2016 August 26.
Published in final edited form as:













Methods—We analyzed the RNA expression of 5 tissue samples from subjects diagnosed with 
oropharyngeal squamous cell carcinoma, 2 HPV+ and 3 HPV−, using Affymetrix GeneChips. The 
relative difference between the average gene expressions of the HPV+ and HPV− samples was 
assessed, based on the fold change (log2-scale).
Results—Our analysis revealed 10 up regulated molecules (Mup1, LRP1, P14KA, ALYREF, and 
BHMT) and 5 down regulated ones (PSME4, KEAP1, ELK3, FAM186B, and PRELID1), at a 
cutoff of 1.5-fold change. Ingenuity Pathway Analysis showed the following biological functions 
to be affected in the HPV+ samples: cancer, hematological disease, and RNA post-transcriptional 
modification. QRT-PCR analysis confirmed only the differential regulation of ALYREF, KEAP1, 
and FAM186B genes.
Conclusion—The relevant methodological procedures described are sufficient to detect the most 
significant biological functions and pathways according to the HPV status in patients with 
oropharyngeal cancer in Puerto Rico.
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Oral cavity and pharyngeal cancer (OCPC) is the 4th and 12th most common cancer type in 
Puerto Rico (PR) among men and women, respectively (1). However, PR shows higher 
incidence of OCPC than any other racial/ethnic group in the US (3). The high incidence of 
OCPC represents a significant economic burden for PR. In 2004, the economic impact of 
OCPC in PR was approximately 6% (more than $3.6 million) of the total cancer costs (4).
Although a substantial percentage of OCPC is attributed to alcohol or tobacco (or both) 
exposure, approximately one quarter of the malignant cases in men and half of those in 
women in PR cannot be so attributed to these exposures (5). For example, previous studies 
indicate that the human papilloma virus (HPV) is a major risk factor for oropharyngeal 
squamous cell carcinoma (6,7). According to Kreimer et al.’s meta-analysis of the relevant 
data published in 2005 the prevalence in the US of oral HPV infection in men and women 
aged from 14 to 69 years was 6.9% (95% CI: 5.7%–8.3%); for HPV type 16 (HPV16), the 
prevalence was 1.0% (95% CI: 0.7%–1.3%) (8). It is estimated that the prevalence of HPV 
in patients with oropharyngeal cancer is about 36%, with HPV16 being the commonest type 
(~86%) in all HPV-positive (HPV+) tumors (8). This infection has been associated with age, 
sex, number of sexual partners, and current number of cigarettes smoked per day (9). 
However, clinically relevant HPV infection involves the oncoproteins coded by early viral 
genes E6 and E7. The E6/E7 mRNA method confirms the presence of transcriptionally 
active HPV-related head and neck squamous cell carcinoma, which has a strong predilection 
for the oropharynx and is strongly associated with high levels of p16 expression (10).
Most tumors with active HPV16 involvement have high p16 (INK4a) levels, low pRb levels, 
low cyclin D1 levels, and normal p53 levels; this pattern is significantly different from the 
pattern observed in HPV-negative (HPV−) tumors (11). Some HPV16+ tumors have been 
found to lack viral RNA expression patterns (11). In addition, HPV+ OCPC patients tend to 
have a better overall prognosis than do their HPV− counterparts, with HPV status appearing 
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to affect therapeutic response and, consequently, the risk of progression is reduced and the 
survival rate is improved (12).
Molecular and epidemiological profiles have suggested that oropharyngeal squamous cell 
carcinoma (OSCC) comorbid with HPV+ is a distinctive disease entity from that which is 
comorbid with HPV−, differing both in terms of genome-wide expression profiles as well as 
in clinical outcomes (13). The full understanding of these differences in diverse populations 
represents an important step in the development of effective personalized treatments for this 
malignancy. However, molecular information regarding HPV infection and its effect on 
oropharyngeal cancer as pertains to Hispanics in PR and those the US is very limited, 
despite the fact that the incidence of this malignancy is rather high in PR (3). The aim of this 
study was to describe a methodology that could be used to identify molecular networks 
(algorithmically generated pathways with a complex interaction between genes) that can 
themselves be used to identify overrepresented signaling and metabolic canonical pathways, 
based on the differential gene-expression profiles between HPV+ and HPV− samples from 
OSCC patients in PR.
Methods
All the study procedures have been detailed in order to identify the molecular networks 
associated with the gene expression profiles between HPV+ and HPV− tumors of OSCC 
patients in PR. These networks identify particular genes (called focus genes) as representing 
significant biological function. The specific steps recommended to identify these types of 
genes are as follows:
i) Participant recruitment
The participants in this study were individuals with an initial diagnosis of OSCC who visited 
the HIMA San Pablo Hospital in Caguas, PR, from February through July 2012. The 
inclusion criteria were 1) being at least 21 years of age and 2) having undergone surgery as 
treatment for the diagnosed OSCC or having had a biopsy to confirm the original OSCC 
diagnosis. Individuals were excluded from the study if 1) they could not voluntarily consent 
to their participation in the study, 2) the period of time after their having been diagnosed 
with OSCC was greater than 12 weeks, or 3) they had a previous cancer diagnosis and/or 
had received treatment (radiotherapy and/or chemotherapy) before ascertainment and 
recruitment. Only those cases with a confirmed OSCC diagnosis were evaluated in this study 
(n = 7).
The sources of data were personal interviews (socio-demographic and risk-factor data), a 
medical record review (OSCC subsite and stages), and fresh tissue samples (HPV status and 
gene-expression profiling). Fresh tissue was collected during each participant’s surgery or 
by performing a biopsy on him or her. Upon performing sample quality control, we 
ascertained that the samples from 2 of the 7 participants contained degraded RNA; thus, only 
5 samples were analyzed.
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All the participants consented to participate in the study, which was approved by the 
Institutional Review Board of the University of Puerto Rico Medical Sciences Campus 
(UPR-MSC) (protocol number: A9240112).
ii) HPV status
Human HPV DNA detection was performed via a nested-PCR strategy using PGMY09/
PGMY11 as outer primers and GP5+/GP6+ as inner primers (14–16). Each reaction was 
carried out in a total volume of 25μl, containing 200 ng of gDNA, 12.5 μl of Bullseye HS-
Taq 2X Master Mix (MIDSCI, St. Louis, MO), and 100 nmol/L of pooled PGMY09/11 
primers. PCR was carried out by the activation of Bullseye polymerase (MIDSCI, St. Louis, 
MO) for 15 minutes at 95°C, followed by 35 cycles of 60 seconds each at 94°C, 60°C, and 
72°C, with a final extension of 10 minutes at 72°C. Two microliters of the first-run PCR 
reaction were used as a template for the nested PCR. The conditions for the nested PCR (40 
cycles) were identical to the first-run PCR, with an annealing step at 52°C for 60 seconds. 
The amplified products with the expected size (141 bp) were electrophoresed in 2% agarose 
gels and analyzed using a ChemiDoc imaging system (Bio-Rad, Hercules, CA).
iii) Gene-expression profiling and Validation by qRT-PCR
We analyzed the RNA expression profiles of 5 tissue samples from subjects diagnosed with 
OSCC, 2 HPV+ and 3 HPV−, using Human Gene 2.0 ST Affymetrix GeneChips, at the 
UPR-MSC Research Centers for Minority Institutions Program Center for Genomics in 
Health Disparities and Rare Diseases, using 100 ng of total RNA, as recommended by the 
manufacturer. RNA quality and integrity were assessed by UV absorption analysis (A260/
A280) in a Nanodrop 1000 Spectrophotometer, and by microfluidic analysis, using the 
Agilent 2100 Bioanalyzer with the RNA 6000 Nano LabChip Kit. Only RNAs that had 
acceptable A260/A280 ratios (from 1.7 to 2.1) and RNA integrity numbers (RIN values of 
~10) (17) were used for microarray analysis and validation by quantitative reverse 
transcription PCR (qRT-PCR). For qRT-PCR, 10 ng of total RNA were analyzed in duplicate 
with primer sets obtained from the Qiagen QuantiTect Primer Assay collection and the 
QuantiFast SYBR Green RT-PCR Kit (Valencia, CA) for amplification in a StepOne Plus 
Real-Time PCR System and the StepOne Software (Thermo Fisher Scientific Inc., Grand 
Island, NY) for the analysis of the qRT-PCR results. In order to obtain the fold changes 
(FCs) for all the genes evaluated for differential expression from HPV+ vs. HPV− tumor 
RNA samples, we used the glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene as a 
housekeeping gene. The relative quantification values were calculated by the ΔΔCT method 
(18).
From a total of 133,318 probesets, each gene’s expression levels were obtained for each 
tissue sample using the Affymetrix GeneChip® Human Gene 2.0 ST Arrays. Then, the 
statistical method of principal component analysis (PCA) was used to identify potential 
clusters of subjects based on the HPV status (19). The cumulative variance of the first 2 
components was 93.6%.
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To assess the gene-expression profiling for every probeset, we initially assessed (with the 
information of the 5 tissue samples) the variability of this expression based on the coefficient 
of variation (CV) computed for the i-th probeset as follows:
After discarding probesets with a CV greater than 50%, we explored the magnitude of the 
association between gene expression and HPV status among sample tissues of OSCC 
patients. The FC was computed for every probeset as follows:
iv) Candidate genes
Once the FC was computed for every probeset, we identified a group of probesets for 
exploring the biological functions affected by the HPV status. The criterion for the selection 
of probesets was based on the FC; probesets with a log2FC greater than 1.5 or a log2FC less 
than −1.5 were included in the list of candidate genes.
v) Ingenuity pathway analysis
We used the IPA software to examine the potential biological functions affected by HPV 
status, based on the list of candidate genes, in OSCC. IPA transforms a list of genes into a 
set of relevant molecular networks (containing approximately 35 genes) that have been 
abstracted into a large network, called the Global Molecular Network, composed of 
thousands of genes and gene products that interact with each other. These networks optimize 
the interconnectivity between a set of user-specified genes (focus genes) that are also in the 
Global Molecular Network and likely represent significant biological function.
The IPA software provides as many interactions as possible between genes, to be most 
informative about how the genes in a given dataset appear to work together at the molecular 
level (www.ingenuity.com). Canonical pathways are generated prior to data input, based on 
the scientific literature, and do not change upon that input. IPA calculates significance based 
on the number of genes/molecules that map to a biological function, pathway, or network. 
The statistical significance assessment is performed based on the Fisher’s exact test (20), 
where the null hypothesis is the proportion of genes mapping to the functions or pathways of 
the list of candidates genes equal to the proportion that map to the same functions or 
pathways in the entire population (total number of genes on the chip). The following 2×2 
contingency table was prepared for this purpose:
Genes Specific function Other functions Total
Candidate genes a (n1-a) n1
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Genes Specific function Other functions Total
Others (m1-a) (n2-m1+a) n2
Total m1 m2 N
where “a” indicates the number of candidate genes with specific function, “ni,” the marginal 
total by type of genes, “mi,” the marginal total of genes with specific functions, and “n,” the 
total number of genes. A Fisher’s exact test provided the probability of finding “a” genes 
with specific functions in the candidate genes from a set of n genes randomly selected from 
the Global Molecular Network. If the null hypothesis is rejected with some significance level 
(i.e., p-value<0.05), there will be evidence of biological effects in the HPV+ group different 
from what would be seen in the HPV− group.
vi) Ranking the networks
In order to rank the networks, a p-score was calculated based on the pFisher exact test-value, 
as follows:
The lower the p-value the higher will be the p-score. A p-score of 3 (p-value = 0.001) 
indicates that there is a 1 in 1,000 probability of getting a network containing at least the 
same number of network-eligible molecules that can be in networks from the Ingenuity 
Knowledge Base.
Results
Most of the participants were male (4 of the 5 individuals). The median age of the group was 
65 years old. The tumors of 2 of the 5 participants were HPV+. The most frequent tumor site 
(60%) was the base of the tongue. Stage IV was commonly observed (4 of the 5 samples) in 
the tumors evaluated.
Based on the intensities of mRNA hybridization of the 133,318 probesets, the results of the 
PCA showed a high concentration of HPV+ tumors when the first 2 components were used; 
however, the HPV− tumors showed more dispersion (Figure 1). In addition, the FC used to 
explore the effect of HPV status showed that approximately 5% of the probesets indicated 
that the intensities of the HPV+ tissue samples were at least double (<−1 or >1 in log2 scale) 
those of the HPV− tissue samples (Table 1). Based on this result, 1758 probesets satisfied 
the criterion of selection for the network analysis of this study (<−1.5 or >1.5 in log2 scale).
Shown in Figure 2 are the 3 most significant HPV-associated networks that were detected 
(using IPA), for OSSC. The results of the IPA indicated that the 5 most significant (p<0.001) 
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HPV-associated diseases and disorders in the OSSC-containing samples were infectious and 
dermatological diseases, immunological and inflammatory diseases, and inflammatory 
response. In addition, according to the IPA results, the 5 most significant molecular and 
cellular functions in this group were cell death and survival, free-radical scavenging, cellular 
growth and proliferation, protein synthesis, and cellular development. The top up regulated 
and down regulated molecules that were reported by IPA, based on the FC in parentheses, 
are listed in Table 2.
Even though we attempted to validate all 10 genes listed in Table 2, only 9 of them could be 
adequately and efficiently amplified by qRT-PCR. Hence, results for relative quantification 
were obtained for 9 of the genes tested (Figure 3). The results of the quantitative reverse 
transcription PCR (qRT-PCR) validation procedure confirmed only the following 3 of those 
9 genes: ALYREF, KEAP1, and FAM186B. The other 6 genes analyzed by qRT-PCR 
showed the differential regulation, but in the opposite sense of the expected difference.
Discussion
Our results showed that differential expression is observed in HPV+ and HPV− samples of 
OSCC. According to the FC results, 877 and 881 probesets were downregulated or up 
regulated (log2FC<−1.5 and log2FC>1.5, respectively), so the ratio was close to 1. The 
relationship between up regulated and down regulated probesets was different from that 
described in the results of Lohavanichbutr et al. (13), where the ratio of up regulated 
probesets to down regulated probesets was 222/77 (2.88). However, our sample size for this 
preliminary study was much smaller than that of the Lohavanichbutr study (119 patients 
with OSCC) (13).
The most relevant pathway network showed that the biological functions affected in the 
HPV+ samples were cancer, hematological disease, and RNA post-transcriptional 
modification. The second most relevant pathway network showed that the biological 
functions affected in the HPV+ OSCC samples were RNA post-transcriptional modification, 
infectious disease, and cancer. The most prominent functions of the affected genes, 
according to Lohavanichbutr et al. (13), were DNA replication, DNA repair, and cell cycling, 
which are key cellular processes frequently dysregulated in cancer.
Jin and collaborators (21) showed that TNF-α played an important role in inflammation, 
immunity, and defense against infection and clearance of HPV. Our results, based on our IPA 
results, suggest that inflammatory disease was one of the 5 most significant HPV-related 
conditions in the OSCC samples.
A recent study of OSCC tumors from German OSCC patients suggests that ALH1A2, 
OSR2, GATA4, GRIA4, and IRX4 gene transcription is regulated by gene-promoter 
hypermethylation, which in turn correlates with HPV status in OSCC tumors (22). However, 
our results did not capture any of these genes in the network analysis based on our 
candidates list. Therefore, since our study had a small number of samples from OSCC 
patients with a Hispanic background, further studies are warranted to describe the biological 
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functions affected by the HPV-infection status of OSCC patients and establish the 
methodological steps to investigate these functions in a Hispanic community.
Even though our study was performed with a small sample, it allowed us to describe a 
methodology that can be used to identify molecular networks that can themselves be used to 
identify overrepresented signaling and metabolic canonical pathways, based on the 
differential gene-expression profiles between HPV+ and HPV− samples from OSCC 
patients in PR. We herein described, in a step-wise fashion, this methodology for those 
investigators who are doing specific genetic analyses of OCPC, but this methodology could 
be applied to other types of comparisons between tumor samples. Hence, we expect to 
expand this project by using a greater number of patients, as we aim to contribute to the 
improvement of oral health in Puerto Rico and in other regions having large Hispanic 
communities, any or all of which have high incidences of this malignancy.
Acknowledgments
We would like to thank Ms. Jessicca Y. Renta and Ms. Mercedes Y. Lacourt for technical assistance in the RNA 
expression analyses and HPV results, respectively. In addition, we thank Dr. Luis E. Ferrer of HIMA-San Pablo 
Caguas Hospital for confirming the HPV results. We acknowledge the collaboration of the UPR/MDACC 
Partnership for Excellence in Cancer Research, NCI (U54CA096297 and U54CA096300); the NIH-NIMHD RCMI 
(G12MD007600) and NIGMS RISE R25GM061838 and R25GM088023 grants; the PRCTRC grant 
(2U54MD007587); the Case Comprehensive Cancer Center CoGEC grant (5R25CA094186-08); and the NPCR of 
the CDC, via the PRCCR grant (1U58DP000782-04). The content is solely the responsibility of the authors and 
does not necessarily represent the official views of the NCI.
References
1. Torres-Cintron M, Ortiz AP, Perez-Irizarry J, et al. Incidence and mortality of the leading cancer 
types in Puerto Rico: 1987–2004. P R Health Sci J. 2010; 29:317–329. [PubMed: 20799522] 
2. [Accessed June 2014] GLOBOCAN 2002 database: summary table by cancer. International Agency 
for Cancer Research Web site. Available at: Url: http://www-dep.iarc.fr/
3. Suárez E, Calo WA, Hernandez EY, et al. Age-standardized incidence and mortality rates of oral and 
pharyngeal cancer in Puerto Rico and among Non-Hispanics Whites, Non-Hispanic Blacks, and 
Hispanics in the USA. BMC Cancer. 2009; 9:129. [PubMed: 19400958] 
4. Ortiz-Ortiz KJ, Perez-Irizarry J, Marin-Centeno H, et al. Productivity loss in Puerto Rico’s labor 
market due to cancer mortality. P R Health Sci J. 2010; 29:241–249. [PubMed: 20799511] 
5. Hayes RB, Bravo-Otero E, Kleinman DV, et al. Tobacco and alcohol use and oral cancer in Puerto 
Rico. Cancer Causes Control. 1999; 10:27–33. [PubMed: 10334639] 
6. Herrero R, Castellsague X, Pawlita M, et al. Human papillomavirus and oral cancer: the 
International Agency for Research on Cancer multicenter study. J Natl Cancer Inst. 2003; 95:1772–
1783. [PubMed: 14652239] 
7. Pintos J, Black MJ, Sadeghi N, et al. Human papillomavirus infection and oral cancer: a case-control 
study in Montreal, Canada. Oral Oncol. 2008; 44:242–250. [PubMed: 17467327] 
8. Kreimer AR, Clifford GM, Boyle P, Franceschi S. HPV type in head and neck squamous cell 
carcinomas worldwide: a systematic review. Cancer Epidemiol Biomarkers Prev. 2005; 14:467–475. 
[PubMed: 15734974] 
9. Gillison ML, Broutian T, Pickard RK, et al. Prevalence of oral HPV infection in the United States, 
2009–2010. JAMA. 2012; 307:693–703. [PubMed: 22282321] 
10. Bishop JA, Ma XJ, Wang H, et al. Detection of transcriptionally active high-risk HPV in patients 
with head and neck squamous cell carcinoma as visualized by a novel E6/E7 mRNA in situ 
hybridization method. Am J Surg Pathol. 2012; 36:1874–1882. [PubMed: 23060353] 
Suárez et al. Page 8













11. Holzinger D, Flechtenmacher C, Henfling N, et al. Identification of oro-pharyngeal squamous cell 
carcinomas with active HPV16 involvement by immunohistochemical analysis of the 
retinoblastoma protein pathway. Int J Cancer. 2013; 133:1389–1399. [PubMed: 23457055] 
12. Fahkry C, Westra WH, Li S, et al. Improved survival of patients with human papillomavirus-
positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 
2008; 100:261–269. [PubMed: 18270337] 
13. Lohavanichbutr P, Houck J, Fan W, et al. Genomewide gene expression profiles of HPV-positive 
and HPV-negative oropharyngeal cancer: potential implications for treatment choices. Arch 
Otolaryngol Head Neck Surg. 2009; 135:180–188. [PubMed: 19221247] 
14. Evander M, Edlund K, Boden E, et al. Comparison of a one-step and a two-step polymerase chain 
reaction with degenerate general primers in a population-based study of human papillomavirus 
infection in young Swedish women. J Clin Microbiol. 1992; 30:987–992. [PubMed: 1315341] 
15. Gillison ML, Castellsagué X, Chaturvedi A, et al. Comparative epidemiology of HPV infection and 
associated cancers of the head and neck and cervix. Int J Cancer. 2013; 134:497–507. [PubMed: 
23568556] 
16. Gravitt PE, Peyton CL, Alessi TQ, et al. Improved amplification of genital human 
papillomaviruses. J Clin Microbiol. 2000; 38:357–361. [PubMed: 10618116] 
17. Schroeder A, Mueller O, Stocker S, et al. The RIN: an RNA integrity number for assigning 
integrity values to RNA measurements. BMC Mole Biol. 2006; 7:3.
18. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic 
Acids Res. 2001; 29:e45. [PubMed: 11328886] 
19. Manly, B. Multivariate Statistical Methods, A primer. 3. Boca Raton, FL: Chapman & Hall/CRC; 
2005. 
20. Rosner, B. Fundamentals of Biostatistics. 7. Independence, KY: Brooks/Cole, Cengage Learning; 
2011. 
21. Jin L, Sturgis EM, Zhang Y, et al. Association of tumor necrosis factor-alpha promoter variants 
with risk of HPV-associated oral squamous cell carcinoma. Mol Cancer. 2013; 12:80. [PubMed: 
23870134] 
22. Kostareli E, Holzinger D, Bogatyrova O, et al. HPV-related methylation signature predicts survival 
in oropharyngeal squamous cell carcinomas. J Clin Invest. 2013; 123:2488–2501. [PubMed: 
23635773] 
Suárez et al. Page 9














Categorization of gene expression in OSCC patients by HPV status, using the method of 
principal components
Note: cas001n, cas002n, and cas003n are HPV-negative
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Principal molecular networks detected
Note: a) Network 1 (p-score = 52 and Focus Molecules = 31) with top functions: Cancer, 
Hematological Disease, and RNA-Post Transcriptional Modifications; b) Network 2 (p-score 
= 44 and Focus Molecules = 28) with top functions: RNA Post-Transcriptional Modification, 
Infectious Disease, and Cancer; c) Network 3 (p-score = 42 and Focus Molecules = 27) with 
top functions: Drug Metabolism, Protein Synthesis, Glutathione Depletion in Liver.
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Relative quantification among selected molecules
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Table 1
Number of probe sets according to the Fold change to compare mRNA expression between HPV-positive and 
HPV− negative individuals
Fold Change (Log 2 scale) Probe sets %
<−1.5 877 0.7
−1.5 to −1.0 4,706 3.5
−1.0 to 1.0 123,466 92.6
1.0 to 1.5 3,388 2.5
>1.5 881 0.7
Total 133,318 100.0
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Table 2
Relative quantification among selected molecules
Characteristic Molecules Microarray FC qRT-PCR RQ










RQ: relative quantification; FC: fold change; ND: not determined
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